Management of dermatologic adverse events from cancer therapies: recommendations of an expert panel
An. bras. dermatol
; 95(2): 221-237, Mar.-Apr. 2020. tab, graf
Article
ي En
| LILACS, ColecionaSUS
| ID: biblio-1130848
المكتبة المسؤولة:
BR1.1
ABSTRACT
Abstract With the development of new cancer therapies, systemic toxicity profile and effects on survival achieved an important improvement. However, a constellation of toxicities has emerged, even more remarkably, cutaneous adverse events. This report, developed by a board of Brazilian experts in oncodermatology, aims to establish a guideline for the dermatological care of oncologic patients. When possible, evidence-based recommendations were made, but in many cases, when strong evidence was not available, a consensus was reached, based on some data supporting therapies combined with personal experiences.
Key words
النص الكامل:
1
الفهرس:
LILACS
الموضوع الرئيسي:
Skin Diseases
/
Drug-Related Side Effects and Adverse Reactions
/
Neoplasms
/
Antineoplastic Agents
نوع الدراسة:
Etiology_studies
/
Guideline
/
Risk_factors_studies
المحددات:
Humans
اللغة:
En
مجلة:
An. bras. dermatol
السنة:
2020
نوع:
Article